Zynex Past Earnings Performance
Past criteria checks 1/6
Zynex has been growing earnings at an average annual rate of 14.3%, while the Medical Equipment industry saw earnings growing at 13.6% annually. Revenues have been growing at an average rate of 33.6% per year. Zynex's return on equity is 21.1%, and it has net margins of 5.3%.
Key information
14.3%
Earnings growth rate
13.2%
EPS growth rate
Medical Equipment Industry Growth | 8.9% |
Revenue growth rate | 33.6% |
Return on equity | 21.1% |
Net Margin | 5.3% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Earnings Miss: Zynex, Inc. Missed EPS By 33% And Analysts Are Revising Their Forecasts
Mar 03Why Investors Shouldn't Be Surprised By Zynex, Inc.'s (NASDAQ:ZYXI) P/E
Jan 24Is Zynex (NASDAQ:ZYXI) Using Too Much Debt?
Aug 03Are Investors Undervaluing Zynex, Inc. (NASDAQ:ZYXI) By 43%?
Mar 30Should You Be Adding Zynex (NASDAQ:ZYXI) To Your Watchlist Today?
Jan 23Short Squeeze Candidate With Low PEG Ratio: Zynex
Oct 05Zynex begins enrollment in blood loss detection trial for CM-1600 monitoring system
Sep 21These 4 Measures Indicate That Zynex (NASDAQ:ZYXI) Is Using Debt Safely
Aug 02Zynex Cures The Pain Of Its Shareholders: Q2 Results
Aug 01Zynex: Upside Looks Well Priced In, Efficiency Headwinds Remain
Jul 25Is Zynex, Inc. (NASDAQ:ZYXI) Trading At A 46% Discount?
Jul 12Zynex June and Q2 orders hit all-time high, re-affirms Q2 and FY22 guidance
Jul 11Is It Time To Consider Buying Zynex, Inc. (NASDAQ:ZYXI)?
Apr 13Zynex (NASDAQ:ZYXI) Seems To Use Debt Quite Sensibly
Mar 23Zynex: Letter Indicates UnitedHealthcare Is Terminating Contract - An Undisclosed Loss Accounting For 50%+ EBITDA
Feb 17Zynex: Turnaround Nears Inevitable End - Largest Payor Cuts TENS Reimbursement, May Eliminate Earnings
Dec 10Revenue & Expenses BreakdownBeta
How Zynex makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 184 | 10 | 136 | 0 |
30 Sep 23 | 186 | 16 | 130 | 0 |
30 Jun 23 | 177 | 17 | 122 | 0 |
31 Mar 23 | 169 | 17 | 114 | 0 |
31 Dec 22 | 158 | 17 | 104 | 0 |
30 Sep 22 | 150 | 18 | 96 | 0 |
30 Jun 22 | 143 | 20 | 89 | 0 |
31 Mar 22 | 137 | 19 | 84 | 0 |
31 Dec 21 | 130 | 17 | 81 | 0 |
30 Sep 21 | 116 | 10 | 77 | 0 |
30 Jun 21 | 101 | 5 | 72 | 0 |
31 Mar 21 | 89 | 5 | 63 | 0 |
31 Dec 20 | 80 | 9 | 53 | 0 |
30 Sep 20 | 69 | 10 | 43 | 0 |
30 Jun 20 | 60 | 11 | 35 | 0 |
31 Mar 20 | 52 | 10 | 30 | 0 |
31 Dec 19 | 45 | 9 | 26 | 0 |
30 Sep 19 | 41 | 9 | 23 | 0 |
30 Jun 19 | 37 | 10 | 19 | 0 |
31 Mar 19 | 34 | 10 | 17 | 0 |
31 Dec 18 | 32 | 10 | 16 | 0 |
30 Sep 18 | 31 | 10 | 14 | 0 |
30 Jun 18 | 29 | 10 | 13 | 0 |
31 Mar 18 | 27 | 9 | 11 | 0 |
31 Dec 17 | 23 | 7 | 10 | 0 |
30 Sep 17 | 18 | 4 | 8 | 0 |
30 Jun 17 | 15 | 3 | 8 | 0 |
31 Mar 17 | 13 | 1 | 8 | 0 |
31 Dec 16 | 13 | 0 | 9 | 0 |
30 Sep 16 | 13 | -1 | 10 | 0 |
30 Jun 16 | 12 | -2 | 10 | 0 |
31 Mar 16 | 12 | -2 | 9 | 0 |
31 Dec 15 | 12 | -3 | 9 | 0 |
30 Sep 15 | 11 | -1 | 9 | 0 |
30 Jun 15 | 13 | -1 | 10 | 0 |
31 Mar 15 | 11 | -6 | 11 | 0 |
31 Dec 14 | 11 | -6 | 11 | 0 |
30 Sep 14 | 12 | -11 | 13 | 0 |
30 Jun 14 | 13 | -12 | 15 | 0 |
31 Mar 14 | 17 | -8 | 21 | 0 |
31 Dec 13 | 22 | -7 | 21 | 0 |
30 Sep 13 | 29 | -2 | 21 | 0 |
30 Jun 13 | 34 | -1 | 21 | 1 |
31 Mar 13 | 38 | 1 | 17 | 1 |
Quality Earnings: ZYXI has a large one-off gain of $2.9M impacting its last 12 months of financial results to 31st December, 2023.
Growing Profit Margin: ZYXI's current net profit margins (5.3%) are lower than last year (10.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ZYXI's earnings have grown by 14.3% per year over the past 5 years.
Accelerating Growth: ZYXI's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: ZYXI had negative earnings growth (-42.9%) over the past year, making it difficult to compare to the Medical Equipment industry average (8.7%).
Return on Equity
High ROE: Whilst ZYXI's Return on Equity (21.1%) is high, this metric is skewed due to their high level of debt.